Urticaria - severe chronic spontaneous urticaria

The PBS subsidises omalizumab for patients with severe chronic spontaneous urticaria.

The PBS subsidises treatment with omalizumab for patients with severe chronic spontaneous urticaria. This is under section 100 of the National Health Act 1953.

Section 100 arrangements

This item is only PBS subsidised for day admitted patients, non-admitted patients, or patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

This item isn’t PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the application form.

Patient eligibility

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing omalizumab.

Authority applications

Applying for initial treatment

Apply for initial authority approval to prescribe PBS subsidised omalizumab to treat severe chronic spontaneous urticaria in writing and either:

All applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS subsidised omalizumab to treat severe chronic spontaneous urticaria can be made either:

Further information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 1 October 2020